Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Active control trials: endpoints beyond conventional efficacy and tolerability measures.

Emilio Perucca

    Epilepsy Research
    |December 27, 2005
    PubMed
    Summary

    Beyond seizure control and tolerability, other factors significantly impact epilepsy patients' quality of life. Exploring diverse clinical trial endpoints, including pharmacokinetic and outcome measures, offers a more comprehensive understanding of drug effectiveness and patient well-being.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Novel epilepsy treatments in clinical development.

    Epilepsy & behavior : E&B·2026
    Same author

    Antiseizure Medications that Did Not Reach the Epilepsy Market: An Assessment of Factors Contributing to Their Failed Clinical Development Over the Last Three Decades.

    Drugs·2026
    Same author

    Evolution of the European Medicines Agency clinical guidelines for epilepsy drug development between 2010 and 2025: A comparative analysis by the ILAE Task Force on Regulatory Affairs.

    Epilepsia·2026
    Same author

    Novel pharmacological therapies in development.

    Current opinion in neurology·2026
    Same author

    Epilepsy, neuroinflammation and cannabidiol What do we know thus far?

    Frontiers in pharmacology·2026
    Same author

    Transcription Factor Binding and Individual Genetic Risk of Valproate Teratogenicity.

    Neurology·2026

    Area of Science:

    • Neurology
    • Clinical Pharmacology
    • Patient-Reported Outcomes

    Background:

    • Conventional clinical trial endpoints in epilepsy focus on seizure frequency and adverse drug reactions.
    • Quality of life is increasingly recognized as a critical outcome, but its determinants are complex.
    • Standard measures may not fully capture the patient experience or the nuances of drug therapy.

    Purpose of the Study:

    • To highlight the importance of comprehensive clinical trial endpoints in epilepsy research.
    • To advocate for the inclusion of broader outcome measures beyond efficacy and tolerability.
    • To emphasize the value of pharmacokinetic data and patient-reported outcomes.

    Main Methods:

    • Review of current practices in clinical trial endpoint selection for epilepsy.

    Related Experiment Videos

  • Discussion of the limitations of traditional efficacy and tolerability measures.
  • Identification of additional relevant endpoints such as mood, sleep, headache, and quality of life.

    • Main Results:

    • Seizure control and tolerability are important but not the sole determinants of quality of life.
    • Pharmacokinetic endpoints offer valuable insights into optimal drug utilization.
    • Outcome measures assessing mood, sleep, headache, and overall quality of life provide a more holistic view of treatment impact.

    Conclusions:

    • Epilepsy clinical trials should incorporate a wider range of endpoints to fully assess treatment benefits and patient well-being.
    • Integrating pharmacokinetic and patient-reported outcome measures enhances the understanding of drug effects.
    • A comprehensive approach to endpoint selection leads to more informed treatment decisions and improved patient care.